AstraZeneca plc (AZN)
|Net Income (ttm)||3.77B|
|Ex-Dividend Date||Aug 12, 2021|
|Day's Range||56.08 - 58.60|
|52-Week Range||46.11 - 60.45|
|Price Target||62.99 (+7.7%)|
|Est. Earnings Date||Nov 12, 2021|
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbico... [Read more...]
In 2020, AstraZeneca's revenue was $26.62 billion, an increase of 9.16% compared to the previous year's $24.38 billion. Earnings were $3.14 billion, an increase of 156.23%.Financial Statements
According to 7 analysts, the average rating for AstraZeneca stock is "Buy." The 12-month stock price forecast is 62.99, which is an increase of 7.67% from the latest price.
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The planned investment at the Alexion Campus in...
The company's next-generation treatment for breast cancer could become the new standard of care.
(Reuters) -AstraZeneca said on Tuesday it would invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or the main components of medicines.
If all AstraZeneca did in the last year was team with Oxford University in a heroic quest to design, test, and deliver in record time one of the.
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests. What Happened: The Phase 3 DESTINY-...
AstraZeneca PLC (NASDAQ: AZN) is trading higher Monday after the company announced its Enhertu data that was presented at the European Society for Medical Oncology showed reduced risk of disease progres...
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus either carboplatin or cisplatin. The I...
AstraZeneca's EVP on the potential of the pharma giant's new breast cancer drug
AstraZeneca Executive Vice-President of the Oncology Business Unit David Frederickson discusses the drugmaker's Enhertu breast cancer drug trial results.
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial include...
Both stocks have grabbed plenty of headlines over the past year.
They offer products that their customers absolutely can't do without, and they also pay dividends.
AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer patients. The combo therapy topped overall su...
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of albuterol and budesonide developed ...
European Medicines Agency Lists Nerve Disorder As “Very Rare” Side Effect Of AstraZeneca Covid-19 Vaccine
The incidence of the side effect remains extremely rare with only 833 cases being reported worldwide from about 592 million administered doses of the AstraZeneca vaccine.
The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE: JNJ) and AstraZeneca plc (NASDAQ: AZN) to reflect several n...
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.
AstraZeneca's (AZN) Ultomiris receives expanded approval in the EU to treat children and adolescents with PNH, a rare disease.
Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.
The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.
The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above) and adolescents. Alexion became a part ...